SOURCE: Acceleron Equity Research

January 12, 2015 07:31 ET

Updated Coverage Report Focuses on CEL-SCI Corporation

NEW YORK, NY--(Marketwired - Jan 12, 2015) - CEL-SCI Corporation (NYSE MKT: CVM) is the subject of an updated coverage report by Acceleron Equity Research, a stock market research firm focused on emerging companies and technologies.

Interested investors may get more information and a copy of the coverage report at:

  • CEL-SCI Corporation has executed on rapid acceleration in patient enrollment. The Company reported an 8-fold increase in patient enrollment in calendar 2014 over 2013 levels. This proves that CVM, in conjunction with its two new clinical research organizations (CROs), can execute on scaling up and completing the study. It also shows the study design and CVM's Multikine immunotherapy are well accepted by dozens of doctors and top medical facilities that have signed on for the study and are willing to advise their patients to undergo treatment with Multikine.

  • As of January 5, 2015, CEL-SCI Corporation reiterated that it is on track to complete the enrollment of 880 patients in its Phase III trial. As of December 2014, CVM reported 328 patients were enrolled. Given the 800% increase in annual enrollment between 2013 and 2014, we assume CVM will comfortably complete enrollment during calendar 2015.

  • On January 6, 2015, CEL-SCI Corporation reported a trial date has been set for May 4, 2015 in its arbitration suit against its former CRO, inVentive Clinical. CVM filed an arbitration claim seeking at least $50 million in damages against the CRO for breach of contract and fraud. Some analysts believe that the embattled CRO may look to settle out of court, prior to the May court date. A win for CVM in this arbitration could put substantial non-dilutive funding on its balance sheet, potentially enough to complete its Phase III trial with no further fundraising. With its current $65 million market cap, a $50 million settlement is more than meaningful and should boost CVM's valuation substantially.

  • In December CEL-SCI Corporation announced it had added 7 more clinical sites in 6 more countries bringing it very close to the target 20 countries slated to participate in the study. By conducting the largest, global study of its kind, CVM is positioning itself to apply for marketing approval for Multikine in the U.S. and the majority of regulatory agencies around the world. The treatment of head and neck cancer is a $6 billion annual global market.

About Acceleron Equity Research

Acceleron is a market intelligence service that focuses on identifying and analyzing technically-complicated companies and equities. Acceleron offers a subscription model product to investors and funds with an emphasis in the emerging markets.

Contact Information

  • Media Contact:
    M. Morhamus
    Acceleron Equity Research